Key result
BNT162b2 vaccination is linked to transient significant blood pressure spikes in ~1% of recipients.
Why the study?
The frequency and characteristics of a significant blood pressure increase after Pfizer-BioNTech BNT162b2 vaccination among healthcare workers remained to be examined.
What is the frequency and clinical course of significant blood pressure increase following BNT162b2 mRNA COVID-19 vaccination in healthcare workers?
Observational (n=797)
No
What is the frequency and clinical course of significant blood pressure increase following BNT162b2 mRNA COVID-19 vaccination in healthcare workers?
Significant blood pressure elevation following BNT162b2 mRNA vaccination is rare (<1%), transient, and benign, though it tends to occur in older individuals and recur after the second dose.
Answers are grounded in this paper and cite their sources.
Rare transient BP rises after BNT162b2 warrant caution in older recipients; leaves open causality and generalizability beyond this cohort.
This brief report examined the frequency and characteristics of a significant blood-pressure (BP) increase after Pfizer-BioNTech BNT162b2 vaccination among healthcare workers who were advised to measure their BP at home. A total of 797 participants (mean age 48.1 ± 10.8 years, 63% women, 39% smokers) were included in the analysis. Seven participants reported an increase in their BP (three in the range of grade 2 and four in the range of grade 3 hypertension). Only one participant had a history of treated hypertension. The BP increase was observed at the end of the first week after the first dose, lasted for 3 to 4 days, and recurred promptly after the second dose. Only one case required hospitalization, mainly due to a history of cardiovascular disease (follow-up). Individuals experiencing a BP increase compared with those not reporting issues with their BP had a higher mean age and similar distribution of sex and non-smoking status. In conclusion, a significant BP increase after Pfizer-BioNTech vaccination seems to be rare and of a benign and transient nature. Monitoring the BP before and after vaccination might be advisable only for selected individuals with a high cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Syrigos et al. (2022) conducted an observational in COVID-19 vaccination among healthcare workers (n=797). BNT162b2 mRNA COVID-19 vaccination was evaluated on Significant blood pressure increase (grade 2 or grade 3 hypertension) after BNT162b2 vaccination. BNT162b2 mRNA COVID-19 vaccination was associated with a significant transient blood pressure increase in 7 of 797 healthcare workers, recurring after the second dose.
Synapse has enriched 10 related papers. Consider them for comparative context: